Skip to content

Clinical study on Evecare forte tablets for the management of Polycystic Ovarian Symdrome (PCOS)

Evaluation of Safety and Efficacy of Evecare Forte Tablets in PCOS (Polycystic Ovarian Disease): A randomized Comparator Double Blinded Clinical Study - EFTAPCOS

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/014204
Enrollment
40
Registered
2018-05-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Female Subjects with Polycystic Ovarian Syndrome

Interventions

Intervention1: Evecare forte tablets: 1 Tablet twice daily for a period of 3 months. Control Intervention1: Metformin: 1 Tablet twice daily for a period of 3 months.

Sponsors

The Himalaya Drug Company
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Females aged Between 18 years to 45 Years. 2.Women with signs and symptoms of PCOS like irregular menstrual cycles, weight gain, biochemical/clinical hyperandrogenemia, hirsutism etc. 3.History of PCOS with 4.PCOS confirmed by Clinical and or biochemical and or ultrasonographical findings. 5.Willingness to sign consent for study including participation with collection of blood specimens.

Exclusion criteria

Exclusion criteria: 1.Patients who is not using oral contraceptive pills, hormonal treatment or IUCDs. 2.Patients who had no systemic illness like hypertension, renal disease, tuberculosis, hepatic disease, diabetes, coagulation disorder, etc. 3.Patients with organic lesion of the reproductive tract especially any benign or malignant growth, extensive cervical erosion, cervical polyps, endometriosis. 4.Patients with severe Hepatic or cardiac or mental illness. 5.Patients unwilling to provide informed consent or abide by the requirements of the study.

Design outcomes

Primary

MeasureTime frame
1. Regularisation of the frequency and variability of menstrual cycle. 3.Improvement in hormonal profile 4.Improvement in metabolic profile like Blood glucose and insulin levels, cholesterol, triglycerides, HDL and LDL. 5.To normalise change in ovary on ultrasonography. Timepoint: End of Month 1, End of Month 2 and End of month 3.

Secondary

MeasureTime frame
incidence of adverse events during the study periodTimepoint: Month 1 Month 2 Month 3;overall compliance to the drug treatmentTimepoint: Month 1 Month 2 Month 3

Countries

India

Contacts

Public ContactDr Padmanabha

Rudrappa Health Care & Diagnostics

deepa.kiran@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026